{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T17:13:53Z","timestamp":1724519633640},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejim.2016.10.009","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T13:45:18Z","timestamp":1477575918000},"page":"52-60","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Xiao-Xiao","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yuan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Nan","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Shuai","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2016.10.009_bb0005","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report","volume":"106","author":"Third Report of the National Cholesterol Education Program (NCEP)","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2016.10.009_bb0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2013.09.020","article-title":"Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey","volume":"231","author":"Reiner","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2016.10.009_bb0015","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMra1106700","article-title":"Proprotein convertases in health and disease","volume":"365","author":"Artenstein","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2016.10.009_bb0020","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2016.10.009_bb0025","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2016.10.009_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4093\/dmj.2015.39.2.87","article-title":"New drugs for treating dyslipidemia: beyond statins","volume":"39","author":"Ahn","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.ejim.2016.10.009_bb0035","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2016.10.009_bb0040","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-015-0460-4","article-title":"Evolocumab: first global approval","volume":"75","author":"Markham","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2016.10.009_bb0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/14712598.2014.902929","article-title":"Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin\/kexin type 9: the available clinical evidence","volume":"14","author":"Cicero","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ejim.2016.10.009_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2016.10.009_bb0055","series-title":"NLA Recommendations for Patient-Centered Management of Dyslipidemia (Draft)","author":"Jacobson","year":"2014"},{"key":"10.1016\/j.ejim.2016.10.009_bb0060","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Loke","year":"2011"},{"key":"10.1016\/j.ejim.2016.10.009_bb0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2016.10.009_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejim.2016.10.009_bb0075","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"1088-1101","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.ejim.2016.10.009_bb0080","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2016.10.009_bb0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2016.10.009_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.10.009_bb0095","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2014primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2016.10.009_bb0100","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2016.10.009_bb0105","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2016.10.009_bb0110","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2016.10.009_bb0115","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.10.009_bb0120","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.10.009_bb0125","first-page":"A12344","article-title":"Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolemia (CEPHEUS)","volume":"130","author":"Chiang","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2016.10.009_bb0130","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2016.10.009_bb0135","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.10.009_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.001800","article-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis","volume":"1","author":"Jones","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2016.10.009_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/oxfordjournals.aje.a116977","article-title":"Changes in serum cholesterol level and mortality: a 30-year follow-up the Finnish cohorts of the seven countries study","volume":"139","author":"Pekkanen","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejim.2016.10.009_bb0150","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2016.10.009_bb0155","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bmj.332.7553.1330","article-title":"Should we lower cholesterol as much as possible?","volume":"332","author":"Ravnskov","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2016.10.009_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","volume":"55","author":"Arsenault","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2016.10.009_bb0165","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non\u2013HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2016.10.009_bb0170","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1515\/CCLM.2004.254","article-title":"The apoB\/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk","volume":"42","author":"Walldius","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ejim.2016.10.009_bb0175","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516303648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516303648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T23:23:31Z","timestamp":1568503411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620516303648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"alternative-id":["S0953620516303648"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2016.10.009","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}